RxRxBriefing
Pharma

Vertex VRTX

VERTEX PHARMACEUTICALS INC / MAPharmaceutical PreparationsMA

Pipeline — registered trials by phase

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
— · Cystic Fibrosis · Completed · est. 2017-09
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
— · Cystic Fibrosis · Completed · est. 2021-10-29
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
— · Cystic Fibrosis · Completed · est. 2017-09
Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
— · Cystic Fibrosis · Completed · est. 2013-10
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
— · Cystic Fibrosis · Completed · est. 2018-12-18
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
— · Cystic Fibrosis · Completed · est. 2022-12-14
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
— · Primary Membranous Nephropathy · Recruiting · est. 2028-12-29
Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
— · Acute Pain · Completed · est. 2023-12-15
A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation
— · Cystic Fibrosis · Completed · est. 2020-10-28
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
— · Cystic Fibrosis · Completed · est. 2019-07-17
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older
— · Cystic Fibrosis · Completed · est. 2024-02-24
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
— · Cystic Fibrosis · Completed · est. 2026-01-29
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
— · Rheumatoid Arthritis · Completed · est. 2014-07
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
— · Cystic Fibrosis · Completed · est. 2015-12
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
— · Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation · Completed · est. 2016-04
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
— · Cystic Fibrosis · Completed · est. 2017-01-20
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
— · Cystic Fibrosis · Completed · est. 2023-07-05
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
— · Cystic Fibrosis · Active Not Recruiting · est. 2026-10-30
Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
— · Acute Pain · Completed · est. 2023-08-25
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
— · Diabetic Peripheral Neuropathic Pain · Recruiting · est. 2027-05-31
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
— · Cystic Fibrosis · Completed · est. 2023-01-09
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
— · Cystic Fibrosis · Completed · est. 2023-08-22
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
— · Cystic Fibrosis · Completed · est. 2016-09
A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
— · Cystic Fibrosis · Completed · est. 2023-10-02
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
— · Cystic Fibrosis · Completed · est. 2020-06-12
Source: ClinicalTrials.gov (trials where Vertex is lead sponsor; 82 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.

SEC filings — insider trading forms excluded

Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.